BCL2 and B-cell chronic lymphocytic leukemia: In CLL, the BCL-2 Gly101Val mutation (i.e., the substitution of glycine at position 101 of the BCL-2 protein by valine) causes an approximately 180-fold reduction in the affinity of venetoclax for BCL-2 (22).